Now, you can access and share the interpretative power of QIAGEN Ingenuity Pathway Analysis (IPA) in an easy-to-consume format – without installing any extra software. IPA Interpret identifies and summarizes the biological themes in your results with the help of AI, creating a shareable, interactive report.

You will learn how to:

• - Create an IPA Interpret report that can be easily shared with others

• - Gain valuable insight into critical biological pathways, key regulators and more with just a few clicks

• - Easily customize charts, such as the highly popular volcano bubble chart, taking advantage of new features introduced with recent updates

• - Export both graphical and tabular results

In this 90-minute training session, you will learn how to identify target mRNAs for your miRNAs of interest and associate them with pathways, diseases, biological functions, tissues and cell types.

Topics that will be covered include:

• How to analyze miRNA-seq datasets alone or both miRNA and corresponding mRNA datasets together

• How to use QIAGEN IPA without a dataset, using miRNA IDs

• Introduction to databases and curated content specific to miRNA

• How to effectively apply various filters and functionalities to identify biomarkers, key targets and biological mechanisms

This is the first part of a series on how you can easily turn your ‘omics data into actionable insights using QIAGEN Ingenuity Pathway Analysis (IPA). Here, we'll focus on setting up your dataset for IPA upload and analysis.

You will learn:

• The IDs, measurement types and formats that IPA supports

• How IPA uses your data for statistical tests and prediction scoring

• The different types and parameters of a Core Analysis

• Best practice tips from our expert

About this series

From ‘Omics to Insights: Data Analysis Fundamentals with IPA

Do you find ‘omics data analysis overwhelming? Good news: it doesn’t have to be.

Discover how you can easily turn your ‘omics data into actionable insights with QIAGEN Ingenuity Pathway Analysis (IPA), an advanced tertiary analysis program for your RNA-seq, proteomics or metabolomics dataset. Learn how to search the QIAGEN Knowledge Base, the rich, expert-curated content that powers IPA. Explore the biological landscape around a gene of interest, formulate promising hypotheses and uncover potentially novel connections – without worrying about programming or paywalls.

As hereditary NGS testing grows more complex, clinical labs must interpret variants with greater speed and accuracy. This webinar introduces Franklin by QIAGEN, now integrated with HGMD Professional, combining AI-powered workflows and automated ACMG annotation with the leading expert-curated germline database. Together, they enable faster, evidence-backed interpretation, reduce manual review, and boost reporting confidence by minimizing missed clinically relevant findings.

In this webinar, you’ll see how Franklin + HGMD accelerates variant matching, streamlines VUS assessment, supports long-read sequencing, and delivers instant access to curated clinical and functional evidence—all through a unified interpretation workflow.

Key highlights include:

• Integrated ACMG-based annotation + automatic literature curation for evidence-backed interpretation

• Instant variant matching to quickly identify known, reported, or novel variant

• Faster VUS resolution with direct access to relevant publications and functional data

• Minimal manual literature search with direct links to HGMD Professional in-platform

• Long-read sequencing support for interpreting complex alleles and structural variants

As hereditary NGS testing grows more complex, clinical labs must interpret variants with greater speed and accuracy. This webinar introduces Franklin by QIAGEN, now integrated with HGMD Professional, combining AI-powered workflows and automated ACMG annotation with the leading expert-curated germline database. Together, they enable faster, evidence-backed interpretation, reduce manual review, and boost reporting confidence by minimizing missed clinically relevant findings.

In this webinar, you’ll see how Franklin + HGMD accelerates variant matching, streamlines VUS assessment, supports long-read sequencing, and delivers instant access to curated clinical and functional evidence—all through a unified interpretation workflow.

Key highlights include:

• Integrated ACMG-based annotation + automatic literature curation for evidence-backed interpretation

• Instant variant matching to quickly identify known, reported, or novel variant

• Faster VUS resolution with direct access to relevant publications and functional data

• Minimal manual literature search with direct links to HGMD Professional in-platform

• Long-read sequencing support for interpreting complex alleles and structural variants

Accurate clinical interpretation of somatic cancer variants is critical for diagnosis and guidance of precision oncology treatment. Without shared standards, laboratories and clinical decision-support (CDS) systems have implemented independent approaches, leading to significant variability and highlighting a need for standardization. 

Through a collaborative effort, ClinGen, the Cancer Genomics Consortium (CGC) and the Variant Interpretation for Cancer Consortium (VICC) have developed a framework for standardized classification. In this webinar, we will evaluate these standards and compare their classifications with results from the QIAGEN Clinical Insight (QCI) Interpret CDS system.

You will learn: 

• Understand ClinGen/CGC/VICC standards for variant classification
  Learn how these expert-developed guidelines define and standardize somatic cancer variant classification.

• Compare software classifications with guideline-based human assessments
  See how classifications from the ClinGen/CGC/VICC standards compare with those generated by QCI Interpret.

• Best practices to use guidelines and tools together
  Discover how to combine expert guidelines with clinical decision support tools for more reliable variant interpretation.

This hands-on workshop will cover a highly requested use case using OmicSoft Explorer and IPA Interpret, two new features that QIAGEN IPA* and OmicSoft customers can now access.

Specifically, the trainer will go over how to:

• Easily search for deeply curated high-quality 'omics datasets (RNA-seq, scRNA-seq, etc.) based on user-defined criteria (disease name, drug treatment, etc.) curated from sources such as GEO, SRA, TCGA and more

• Explore project details to gain a better understanding of the experimental setup and sample metadata

• Study volcano plots to identify biomarkers associated with conditions of interest

• Generate sharable pathway analysis reports that provide insights into disease pathology, drug mechanism of action, cellular processes and more

*with a premium license.

IPA Interpret and OmicSoft Explorer are now available through both IPA and OmicSoft. Learn more.

This webinar will introduce you to the Long Read Support plugin for Oxford Nanopore and PacBio sequencing reads in QIAGEN CLC Genomics Workbench.

Learn how to:

• - Download and install needed plugins

• - Import data required for the analysis

• - Perform long read de novo assembly

• - Map reads to a reference and visualize an assembly

• - Use BLAST to investigate the contigs

• - Use additional long read tools: polish with short reads, structural variant calling

• - Use genome finishing tools: analyze and assemble contigs

• - Use analytical tools: RNA-seq analysis for long reads, classify long read amplicons for metagenomics

This 90-minute training session will show you how QIAGEN Ingenuity Pathway Analysis (IPA) helps visualize molecular intricacies and variations at multiple levels, such as transcriptome, proteome and metabolome. Through a series of brief technical vignettes, we will demonstrate how to:

• - Generate associations among molecular signatures obtained via integrating multi-omics data

• - Extract mechanisms from multi-omics data for precision medicine

• - Disease stratification based on multi-omics profiles

• - Map disease networks among targets and indications

The early stages of drug development are inherently high-risk; molecule screening, target evaluation and lead refinement can take years and cost millions of dollars – often have little to show for the effort. Indication expansion and drug repurposing can open new avenues of possibility, after careful evaluation of the relationships between the drug, its targets and the new disease context. These connections can be uncovered by mining curated, causal knowledge graphs, which inform smarter target identification.

Learn how to evaluate targets and drugs in this oncology-focused webinar, which examines BRAF as a target in multiple myeloma. Also, we’ll evaluate different drugs in clinical trials with an analysis that covers the GOT-IT assessment blocks for drug evaluation. These blocks, developed by the GOT-IT (Guidelines On Target Assessment for Innovative Therapeutics) working group, are part of a target assessment framework that supports robust, reproducible data.

We’ll cover how to:

• - Apply the GOT-IT framework to target evaluation and indication expansion

• - Uncover causal relationships between existing drugs and new diseases with our curated knowledge graphs

• - Make informed decisions based on concrete data, including toxicity, adverse events and competing drugs in clinical trials